3 This presentation includes forward-looking statements. Words such as “believes,” “plans,” “expects,” “anticipates,” and “will” are intended to identify forward-looking statements, and are based on our current beliefs and expectations. They include statements regarding: our belief that we have completed the clinical development program for Acetavance, the potential results of the ongoing review of Phase 3 clinical trial data for Omigard, the timeframes in which we expect to submit NDAs for our product candidates, the anticipated clinical efficacy, safety, labeling claims, medical need, pricing, market potential and the availability of adequate patent and regulatory exclusivity protection for our product candidates. Our actual results may differ materially from those included in this presentation due to the risks and uncertainties inherent in our business, such as: the FDA may require us to complete additional trials, testing or other requirements prior to submitting NDAs for our product candidates; final analyses of data from our clinical trials may vary from initial analyses; the FDA may not agree with our interpretation of the results of our clinical trials; our clinical trials may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials; we expect intense competition and pricing pressure for our product candidates, and new products may emerge that provide different or better therapeutic alternatives; the FDA may not agree with changes we have proposed in the statistical analysis plan for our Phase 3 clinical trial of Omigard, and we cannot be certain how the FDA will analyze the results of the trial; our clinical trial data may not indicate sufficient therapeutic efficacy for our product candidates, and these data or adverse event reporting data from countries where Acetavance is approved, may indicate that adverse side effects are more prevalent or severe than anticipated; we may experience delays in completing important manufacturing development activities, which would delay our NDA submissions; the performance of third parties on whom we rely to complete key development activities may be substandard, late, or may be of insufficient quality to include in our NDAs; we may require substantial additional funding to complete our development programs and, if approved, to launch our product candidates, and we may not be able to raise sufficient capital when needed, or at all. These and other risks are detailed in our prior press releases and periodic public filings with the Securities and Exchange Commission, and we encourage you to read them carefully. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. Forward-looking statements Cadence, Acetavance and Omigard are trademarks of Cadence Pharmaceuticals, Inc. © 2009 Cadence Pharmaceuticals, Inc. All rights reserved. Tylenol® is a registered trademark of McNeil Laboratories, Inc. Perfalgan™ is a trademark of Bristol-Myers Squibb Company |
